Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab-Reference-Cited by-同舟云学术

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

Published:2014-02-03 Issue:2 Volume:9 Page:e87705
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Tarhini Ahmad A.,Edington Howard,Butterfield Lisa H.,Lin Yan,Shuai Yongli,Tawbi Hussein,Sander Cindy,Yin Yan,Holtzman Matthew,Johnson Jonas,Rao Uma N. M.,Kirkwood John M.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference39 articles.

1. Final version of 2009 AJCC melanoma staging and classification;CM Balch;J Clin Oncol,2009

2. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial;CM Balch;Ann Surg,1993

3. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas;CM Balch;Ann Surg Oncol,2001

4. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial;CP Karakousis;Ann Surg Oncol,1996

5. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer;LG Estevez;Clin Cancer Res,2004

Cited by 257 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge;International Journal of Molecular Sciences;2024-08-31

2. An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-Cancer Vaccines;Current Genomics;2024-08-30

3. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis;Frontiers in Immunology;2024-05-24

4. The immunosuppressive landscape in tumor microenvironment;Immunologic Research;2024-05-01

5. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer;Oncotarget;2024-03-19